An opt-out system seems to help, but there’s more work to do to meet performance goals endorsed by the AHA and ACC.

Please provide your email address to receive an email when new articles are posted on . Across three measures of oxygen utilization, researchers observed improvement with pegtarazimod vs. placebo.

Memorial Hospital of Rhode Island and Brown University, Pawtucket, Rhode Island, USA Correspondence to Dr F Dennis McCool, Pulmonary, Critical Care and Sleep Medicine, Memorial Hospital of Rhode ...

Rationale In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO compared with conventional ...

Correspondence to Professor Siew C Ng, Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; siewchienng{at}cuhk.edu.hk Objective Although COVID-19 is primarily a ...

Douglas Kondo, MD, Associate Professor (Clinical), is an adult and child psychiatrist, and brain imaging researcher who works at the Salt Lake City VA Healthcare System (SLCVAHCS), in the Rocky ...

The SOFA-2 score included new definitions, new variables, and revised thresholds to categorize the severity of organ dysfunction in critical illness. The updates reflected changes in practice, ...

3 Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d’Angers, Angers, France 4 Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Tours, Tours, ...

Acute right ventricular failure (ARVF) is commonly seen in the intensive care unit and constitutes a significant clinical challenge, with associated high in-hospital mortality. Recently, the treatment ...